Emergent BioSolutions Inc. Buyback
OLI recorded this information on 11/11/2021
Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized management to repurchase up to $250 million of the company's common stock from time to time on the open market or in privately negotiated transactions. This repurchase authorization expires on November 11, 2022.
Emergent BioSolutions is a life sciences company focused on providing a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). Co. is focused on products and solutions that address the following five distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). Co. has a product portfolio of ten marketed products (vaccines, therapeutics, and drug-device combination products).
EBS SEC Filing Email Alerts Service
Open the EBS Page at The Online Investor »
Free EBS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Buy (2.80 out of 4)